Innovating Treatments for Rare Neurological Disorders

In this episode of The Business Gay Podcast, host Calan Breckon speaks with Anmol Nagpal.

Anmol is a neuroscientist-turned-entrepreneur with over 10 years of experience in academia, healthcare, and entrepreneurship, with research published in top journals like Nature Medicine and Proceedings of the National Academy of Sciences also known as PNAS. Since March 2023, he has been the Entrepreneur-in-Residence at District 3 Innovation, coaching over 50 early-stage life science startups and managing a portfolio of 25 later-stage biotech ventures, helping them accelerate their path to commercialization. Anmol holds a Master of Science in Neuroscience with a focus on Fragile X Syndrome and other genetic brain disorders. He also has a Bachelor of Arts and Science from McGill University, as well as a Graduate Diploma in Business from Queen’s University.

Watch on YouTube

---

► Today’s Sponsor is Kit - start your email list today

Join the email list for news and updates

---

Links mentioned in this episode:

• Nospharma.ca
• Anmol Nagpal on LinkedIn

---

Key Takeaways for quick navigation:

• [00:44] Nospharma focuses on treatments for fragile X syndrome, a rare brain disease.
• [01:23] The company was founded by scientists combining efforts to commercialize a treatment for fragile X syndrome.
• [05:02] Nospharma’s approach targets both brain cell communication and blood flow, offering a holistic treatment.
• [07:01] Utilizing existing drugs, Nospharma speeds up treatment availability, reducing development time and cost.
• [09:01] The company is preparing for FDA approval to begin clinical trials on patients.
• [13:28] Nospharma includes female mice in trials to gather robust data applicable to both genders.
• [14:55] Nospharma uses clinical research organizations to maintain flexibility and objective analysis.
• [16:16] Interested individuals can connect with Nospharma via LinkedIn or email; consult physicians for health concerns.